 | | Vol. 13.29 – 5 August, 2021 |
| |
|
|
| Scientists described a novel multi-kinase inhibitor, 108600, that suppressed growth, colony and mammosphere forming capacity of breast cancer stem cell-like cells and induced G2M arrest and apoptosis of TNBC cells.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that hypoxia promoted the growth of breast tumor-repopulating cells through metabolic reprogramming. Hypoxia mobilized transcription factors HIF-1α and FoxO1 and induced epigenetic reprogramming to upregulate cytosolic phosphoenolpyruvate carboxykinase.
[Cancer Research] |
|
|
|
| Macrophages co-cultured with breast cancer cells showed a significant increase in CCL2 expression and promoted β-Catenin-induced breast cancer stem cells (BCSCs) properties, whereas depletion of CCL2 by adding neutralizing antibodies suppressed BSCSs properties.
[Oncogene] |
|
|
|
| The authors reported that a small adaptor protein, SH3BGRL, was upregulated in the majority of breast cancer patients, especially elevated in those with metastatic relapse, indicating it as a marker for the poor prognosis of breast cancer.
[Oncogene] |
|
|
|
| Investigators reported that the upregulated C-MET signaling acted as a compensatory mechanism that sustained the proliferation of chemoresistant cells in which EGFR family signaling was attenuated.
[Cancer Letters] |
|
|
|
| Researchers reported that lipocalin 2, a small secreted glycoprotein belonging to the lipocalin superfamily, was expressed at significantly higher levels in inflammatory breast cancer (IBC) versus non-IBC tumors, independently of molecular subtype.
[Molecular Oncology] |
|
|
|
| In mammary epithelial cells of transgenic mouse models, and breast cancer cell lines, HER2 hyperactivation altered GPCR expression, particularly, Gi/o-GPCRs.
[JCI Insight] |
|
|
|
| The authors screened compounds inhibiting breast cancer cell proliferation with hematopoietic PBX-interacting protein (HPIP) fused with green fluorescent protein as a reporter. A novel agent named TXX-1-10 derived from rimonabant was discovered to reduce HPIP expression and had greater inhibitory effects on breast cancer cell growth and metastasis in vitro and in vivo than rimonabant.
[Cell Death Discovery] |
|
|
|
| Quantitative reverse transcription-polymerase chain reaction was used to detect the expression of WAKMAR2 in invasive breast cancer and normal tissues, and the effect of WAKMAR2 on the regulation of downstream genes in MB-231 and MCF7 cells was studied in vitro.
[Scientific Reports] |
|
|
|
| Scientists provided the transcriptional landscape of TNBC in response to TGFβ activation and subsequent inhibition employing SB431542, selective TGFβ1 Receptor ALK5 Inhibitor.
[Scientific Reports] |
|
|
|
| Researchers focused on the potential involvement and mechanism of LINC00337 in breast cancer (BCa). High-expressed LINC00337 accelerated viability and proliferation of BCa cells, improved the resistance of BCa cells to paclitaxel, and accelerated tumor growth.
[Molecular Immunology] |
|
|
|
| With the help of cell cytotoxicity, the effect of tonkinensine B on MDA-MB-231 cells was investigated. The levels of key apoptosis-associated proteins Bcl-2, Bax, caspase-9, caspase-3 and AKT in MDA-MB-231 cells were analyzed to determine whether tonkinensine B caused apoptosis via the mitochondrial pathway.
[Journal of Pharmacy and Pharmacology] |
|
|
|
|
| The authors summarize the metabolic network and regulatory changes upon breast cancer therapy in terms of cancer pathological and genetic differences and discuss the implications of metabolic imaging with various probes in selecting target beneficiaries for precision treatment.
[Trends in Endocrinology and Metabolism] |
|
|
|
| To understand stratifiers, it is important that the field invests in key understudied areas of research including characterization of the tumor secretome and receptor activation in response to endocrine treatment, and mapping the ER-HER2-growth factor network in the normal and developing mammary gland.
[Endocrinology] |
|
|
|
|
| SpringWorks Therapeutics, Inc. announced that the company will be evaluating mirdametinib, an investigational MEK inhibitor, in a platform study exploring the compound both as a monotherapy and as a combination therapy in advanced solid tumors harboring MAPK-activating mutations.
[SpringWorks Therapeutics, Inc.] |
|
|
|
| Carrick Therapeutics announced a clinical collaboration with Roche to evaluate a novel combination of Carrick’s samuraciclib and Roche’s giredestrant in CDK4/6i resistant HR+, HER2– metastatic breast cancer.
[Carrick Therapeutics (Globe Newswire, Inc.)] |
|
|
|
|
| November 15 – 17, 2021
Virtual |
|
|
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | University of Gothenburg – Gothenburg, Sweden |
|
|
|
| | University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
| | Karolinska Institutet – Stockholm, Sweden |
|
|
|
| | Mayo Clinic Health System – Rochester, Minnesota, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
